Clinical trials: Dermatologic
Non Small Cell Lung Cancer (NSCLC)
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
To assess the impact of prophylactic treatment on the incidence of adverse events in advanced NSCLC patients (post chemotherapy) treated with dacomitinib daily as a single agent.
- Trial name
- ARCHER 1042 (NCT01465802)
- Testing
- Dacomitinib, Doxycycline, Probiotic
- Where
- 81 sites in United States, South Korea
- Volunteers
- 236 people
- Sponsor
- Pfizer
Actinic Keratosis, Keratosis, Actinic
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
The aim of the study is to evaluate the safety and tolerability of PDT for treatment of mild to severe actinic keratosis on the face and scalp in the expanded treatment field using 3 tubes of BF-200 ALA 10% gel (Ameluz®) in…
- Conditions
- Actinic Keratosis, Keratosis, Actinic, Keratosis
- Trial name
- NCT05060237
- Testing
- BF-200 ALA and red light LED lamp
- Where
- 9 sites in United States
- Volunteers
- 112 people
- Sponsor
- Biofrontera Bioscience GmbH
Pain, Phlebotomy
Synera Venipuncture Pain
Synera, which is a heated topical patch containing both lidocaine and tetracaine, is intended to reduce the pain associated with venipuncture and superficial dermatologic procedures by numbing the skin.
- Conditions
- Pain, Phlebotomy, Palliative Care
- Trial name
- NCT01744197
- Testing
- Synera (lidocaine 70mg/tetracaine 70mg)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- US Oncology Research
Psoriasis
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate pharmacokinetic similarity, efficacy, safety and immunogenicity of multiple switches between ustekinumab and ABP 654 compared with continued use of ustekinumab in participants with moderate…
- Trial name
- NCT04761627
- Testing
- Ustekinumab, ABP 654
- Where
- 88 sites in United States, Canada and 6 more
- Volunteers
- 494 people
- Sponsor
- Amgen
Actinic Keratoses
Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year
The objective of this study was to obtain long-term sustained clearance rates for subjects previously treated with imiquimod creams in studies GW01-0702, GW01-0703, GW01-0704 and GW01-0705.
- Trial name
- NCT00668733
- Volunteers
- 179 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Psoriasis
Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis
The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.
- Trial name
- SPIRIT (NCT00244842)
- Testing
- voclosporin
- Where
- 31 sites in Canada
- Volunteers
- 451 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Psoriasis
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.
- Trial name
- NCT02684370
- Testing
- risankizumab, ustekinumab
- Volunteers
- 560 people
- Sponsor
- AbbVie
Dermatologic Complications
Preliminary Study of Peel Force and Discomfort of Removal of Adhesive Barriers in Normal and Peristomal Skin
This purpose of this study is to look at three commercially available ostomy barriers on peristomal (around the stoma) skin. Repeated barrier application and removal over years causes changes to the skin that the investigators…
- Trial name
- NCT02003404
- Testing
- Control Abdominal Skin, Peristomal Abdominal Skin
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hollister Incorporated
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
The primary objective of this study is to evaluate the safety of IMG-007 in adults with moderate-to-severe AD. The secondary objectives are to evaluate the pharmacokinetics and efficacy of IMG-007 in AD patients.
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, AD
- Trial name
- NCT05984784
- Testing
- IMG-007
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Inmagene LLC
Alopecia Areata (AA)
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
- Trial name
- NCT06060977
- Testing
- IMG-007
- Where
- 17 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Inmagene LLC
Wrinkle, Fine Lines
Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions
Subjects are to be enrolled in this clinical study if they are 18 - 55 years old. Up to 120 subjects will be enrolled at multiple study centers.
- Conditions
- Wrinkle, Fine Lines, Crepey Skin, Acne Scars
- Trial name
- NCT05097157
- Testing
- Potenza
- Where
- 4 sites in United States
- Volunteers
- 79 people
- Sponsor
- Cynosure, Inc.
Actinic Keratosis
Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
The purpose of this study is to determine whether imiquimod creams are effective in treating Actinic Keratoses when applied to the face or balding scalp.
- Trial name
- NCT00603798
- Testing
- Imiquimod cream
- Where
- 26 sites in United States
- Volunteers
- 490 people
- Sponsor
- Graceway Pharmaceuticals, LLC